Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

CONMED to purchase New Haven’s Biorez

CONMED Corporation has entered into an agreement to acquire New Haven-based medical technology company Biorez. Biorez is known for its FDA-approved BioBrace implant technology. The...

| By Caitlin Truesdale

Thermo Fisher expands production capacity

Thermo Fisher Scientific has completed an expansion at its dry powder media manufacturing plant, expanding the site’s production arsenal to include technology and materials used in...

| By Caitlin Truesdale

Weekly Roundup – August 11, 2022 

View this email in your browser Weekly Roundup – August 11, 2022  FML recently published an article in TechCrunch explaining convertible notes for startups. Julie Gionfriddo, Director, Advisory...

| By Caitlin Truesdale

BioCT welcomes Josh Geballe to Board of Directors

BioCT welcomes Josh Geballe, MBA, to its Board of Directors Josh is Senior Associate Provost for Entrepreneurship and Innovation at Yale University and Managing Director of Yale...

| By Caitlin Truesdale

Pfizer to acquire hematology company

Pfizer has agreed to acquire Global Blood Therapeutics, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved...

| By Caitlin Truesdale

Career News – August 9, 2022 

View this email in your browser Career News – August 9, 2022  Alexion  Director, CMC Team Lead New Haven Associate Director, Biostatistics New Haven +72 more Arvinas ...

| By Caitlin Truesdale

EvolveImmune names president of R&D

EvolveImmune Therapeutics has appointed Jay S. Fine, Ph.D., as the company’s President of Research and Development. Dr. Fine is an accomplished biopharmaceutical executive with a successful...

| By Caitlin Truesdale

MediSynergics reports positive ongoing developments

MediSynergics reports positive ongoing preclinical development of “ketamine derivative” compounds MS-168 and MS-227 in pain, anxiety, behavior acute toxicity pharmacology, in vitro ADME, and structural elucidation...

| By Caitlin Truesdale

Alexion expansion will double lab floor space

Alexion, AstraZeneca’s Rare Disease group, has announced plans to expand in New Haven by leasing space at the new bioscience tower currently under construction at...

| By Caitlin Truesdale

Weekly Roundup – August 4, 2022 

View this email in your browser Weekly Roundup – August 4, 2022  Monday Arvinas announced John Northcott would join their team as the new Chief Commercial Officer. “I...